tetano
Editor, Senior Moderator
Front Microbiol
. 2022 Jan 14;12:817200.
doi: 10.3389/fmicb.2021.817200. eCollection 2021.
Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019
Marcela Salazar-García[SUP] 1 2 [/SUP], Samyr Acosta-Contreras[SUP] 2 [/SUP], Griselda Rodríguez-Martínez[SUP] 2 [/SUP], Armando Cruz-Rangel[SUP] 3 [/SUP], Alejandro Flores-Alanis[SUP] 4 [/SUP], Genaro Patiño-López[SUP] 5 [/SUP], Victor M Luna-Pineda[SUP] 2 5 [/SUP]
Affiliations
Abstract
World Health Organization (WHO) has prioritized the infectious emerging diseases such as Coronavirus Disease (COVID-19) in terms of research and development of effective tests, vaccines, antivirals, and other treatments. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), the etiological causative agent of COVID-19, is a virus belonging to risk group 3 that requires Biosafety Level (BSL)-3 laboratories and the corresponding facilities for handling. An alternative to these BSL-3/-4 laboratories is to use a pseudotyped virus that can be handled in a BSL-2 laboratory for study purposes. Recombinant Vesicular Stomatitis Virus (VSV) can be generated with complementary DNA from complete negative-stranded genomic RNA, with deleted G glycoprotein and, instead, incorporation of other fusion protein, like SARS-CoV-2 Spike (S protein). Accordingly, it is called pseudotyped VSV-SARS-CoV-2 S. In this review, we have described the generation of pseudotyped VSV with a focus on the optimization and application of pseudotyped VSV-SARS-CoV-2 S. The application of this pseudovirus has been addressed by its use in neutralizing antibody assays in order to evaluate a new vaccine, emergent SARS-CoV-2 variants (delta and omicron), and approved vaccine efficacy against variants of concern as well as in viral fusion-focused treatment analysis that can be performed under BSL-2 conditions.
Keywords: Biosafety Level 3; SARS-CoV-2; glycoprotein; ppVSVΔG-SARS-CoV-2 S; pseudotyped viruses; pseudovirus; vesicular stomatitis virus.
. 2022 Jan 14;12:817200.
doi: 10.3389/fmicb.2021.817200. eCollection 2021.
Pseudotyped Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease 2019
Marcela Salazar-García[SUP] 1 2 [/SUP], Samyr Acosta-Contreras[SUP] 2 [/SUP], Griselda Rodríguez-Martínez[SUP] 2 [/SUP], Armando Cruz-Rangel[SUP] 3 [/SUP], Alejandro Flores-Alanis[SUP] 4 [/SUP], Genaro Patiño-López[SUP] 5 [/SUP], Victor M Luna-Pineda[SUP] 2 5 [/SUP]
Affiliations
- PMID: 35095820
- PMCID: PMC8795712
- DOI: 10.3389/fmicb.2021.817200
Abstract
World Health Organization (WHO) has prioritized the infectious emerging diseases such as Coronavirus Disease (COVID-19) in terms of research and development of effective tests, vaccines, antivirals, and other treatments. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), the etiological causative agent of COVID-19, is a virus belonging to risk group 3 that requires Biosafety Level (BSL)-3 laboratories and the corresponding facilities for handling. An alternative to these BSL-3/-4 laboratories is to use a pseudotyped virus that can be handled in a BSL-2 laboratory for study purposes. Recombinant Vesicular Stomatitis Virus (VSV) can be generated with complementary DNA from complete negative-stranded genomic RNA, with deleted G glycoprotein and, instead, incorporation of other fusion protein, like SARS-CoV-2 Spike (S protein). Accordingly, it is called pseudotyped VSV-SARS-CoV-2 S. In this review, we have described the generation of pseudotyped VSV with a focus on the optimization and application of pseudotyped VSV-SARS-CoV-2 S. The application of this pseudovirus has been addressed by its use in neutralizing antibody assays in order to evaluate a new vaccine, emergent SARS-CoV-2 variants (delta and omicron), and approved vaccine efficacy against variants of concern as well as in viral fusion-focused treatment analysis that can be performed under BSL-2 conditions.
Keywords: Biosafety Level 3; SARS-CoV-2; glycoprotein; ppVSVΔG-SARS-CoV-2 S; pseudotyped viruses; pseudovirus; vesicular stomatitis virus.